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Fifty-four patients with chronic stable angina were studied 
to determine and compare weekly variability of indexes for 
the detection of myocardial ischemia. All patients under- 
went three single-blind placebo periods, each lasting 1 
week. An exercise treadmill test, 24 h ambulatory electro- 
cardiographic (Holter) monitoring (analyzed blindly) and 
an accurate diary of angina1 attacks and nitroglycerin use 
were obtained at the end of each placebo period. An 
unbalanced, completely random component of variance 
analysis was used to calculate a component for within 
subject variability and a component for among subject 
variability. 
The coefficient of variation and percent variation (within 
subjects) of onset of chest pain during exercise were 19% 
and 30%) respectively; the corresponding values were 28 % 
and 33% for onset of 1 mm ST depression, 15% and 15% 
for exercise duration, 44% and 27% for number of ische- 
mic episodes/24 h, 56% and 43% for angina1 frequency and 
55% and 27% for nitroglycerin consumption, respectively. 
With use of this statistical method and variation within 
subjects, the change in the value of each variable necessary 
to exceed those attributable to spontaneous variation was 
determined. The trade-off between repeated measurements 
and number of subjects, the sample size estimated for 
planning studies and the minimal sample size for using 
various designs were also determined. 
Although the data indicate that all indexes for myocar- 
dial ischemia, both during exercise and during daily activ- 
ity, vary considerably, but the exercise variables have less 
variability and are more reproducible. The number of 
ischemic episodes on Holter monitoring has less spontane- 
ous variability than does angina1 frequency or nitroglycerin 
consumption; however, the duration of ischemic episodes 
detected by Holter monitoring is the most variable index. 
(.I Am Co11 Cardiol1989;13:574-9) 
A myocardial ischemic episode can give rise to a series of 
unfavorable cardiac events: myocardial dysfunction (1) 
ST-T changes on the electrocardiogram (ECG) (2), hemody- 
namic changes (3-5), angina (5,6) and cardiac arrhythmias 
(6). These changes can be readily detected during exercise 
and daily activity, and can be used as an indicator of 
myocardial ischemia (7,B). Angina has traditionally been the 
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most frequently used index for myocardial ischemia. How- 
ever, we now know that most myocardial ischemic episodes 
are not associated with angina (9-11); therefore, frequency 
of angina and nitroglycerin consumption may not truly 
represent the total number of ischemic episodes. The ST-T 
changes during an exercise test are relatively reliable as an 
indicator for provoked myocardial ischemia, but they may 
not correlate with spontaneously occurring myocardial isch- 
emia during daily activity. Just as 24 h ambulatory ECG 
(Holter) monitoring for the detection of ST-T changes during 
myocardial ischemia has become an acceptable tool for 
detecting myocardial ischemic episodes (12-14), so have the 
ST-T changes detected on Holter monitoring been recog- 
nized as a useful index for spontaneously occurring myocar- 
dial ischemia, even if the changes are not associated with 
angina (15,16). 
The aim of the present study was to determine and 
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Table 1. Mean and Standard Deviation of Ischemic Variables in Three Treatment Periods 
Exercise 
Onset of chest pain (s) 
Onset of I mm ST depression (s) 
Total duration (s) 
Halter monitoring 
No. of episodes/24 h 
Total duration (min/24 h) 
Subjective symptoms 
Angina1 frequencylwk 
Nitroglycerin consumptioniwk 
No. of Placebo 1 
Subjects (mean t SD) 
49 313 ? 123 
43 246 -i 140 
49 418 ? 143 
44 2.8 t 3.6 
40 66 ? 125 
43 4.8 ? 6.7 
42 4.2 t 7 
Placebo 2 
(mean 2 SD) 
328 2 138 
291 ? 145 
417 ? 149 
2.30 + 3.4 
54 ?I 123 
3.7 2 5.4 
3.4 * 5.3 
Placebo 3 
(mean ? SD) 
360 + 155 
258 ? 170 
473 2 185 
2.4 -t 3.7 
53 +_ 115 
None 
None 
compare the reproducibility and variability of ischemic in- 
dexes from various cardiac tests in patients with chronic 
stable angina. One should be able to use the data to define 
therapeutic end points and guidelines for assessing the 
efficacy of antianginal agents for individual patients and 
clinical trials. 
Methods 
Study patients. We evaluated 65 men (mean age 59 years) 
with chronic stable angina, all of whom had unequivocal 
evidence of coronary artery disease. Forty-two patients had 
coronary artery stenosis detected by coronary angiography; 
13 patients had one vessel disease, 19 had two vessel disease 
and 10 had three vessel disease. Of the remaining 23 patients 
without a prior coronary angiogram, 11 had a history of prior 
myocardial infarction with the presence of pathologic Q 
waves on the ECG and 12 had a positive exercise treadmill 
test for myocardial ischemia. All patients had a history of 
angina pectoris for at least 6 months before entry into the 
study. 
Study protocol. All patients were treated in a single-blind 
manner with placebo for three separate treatment periods, 
each lasting 1 week. All patients had a screening treadmill 
exercise test showing a positive test for exercise-induced 
ischemia before the study. The first two consecutive placebo 
periods were after the patients had been withdrawn from 
antianginal treatment for at least five half-lives. All patients 
were then treated with either a calcium channel blocking 
agent or nitrate for 2 to 3 weeks, followed by the last placebo 
period for I week. Exercise treadmill testing and Holter 
monitoring, done at the same time each day, were performed 
at the end of each placebo period. The patients were asked to 
maintain an accurate diary of their angina1 attacks and 
nitroglycerin consumption. We did not use the third treat- 
ment period, considered a “washout period,” for the anal- 
ysis of angina1 frequency or nitroglycerin consumption be- 
cause the effects of previous antianginal agents may 
influence the occurrence of angina1 attacks during the first 
few days after treatment withdrawal, thereby decreasing 
angina1 frequency. 
Helter ECG monitoring and analysis. Twenty-four hour 
Holter ECG recordings were obtained and analyzed blindly 
by a technician utilizing the compact analog technique. This 
has been found to be a highly reproducible technique for 
detecting the frequency and duration of myocardial ischemia 
when compared with real-time analysis of Holter recordings 
(9,17). ST segment deviation was measured 0.08 s from the J 
junction. Episodes of ECG changes were considered to 
represent ischemia if they were associated with 51 mm of 
ST deviation from the baseline that lasted 230 s. ST-T 
changes associated with bundle branch block or changes in 
QRS complexes were excluded. All ischemic episodes were 
verified by real-time printouts of QRST complexes and 
overread blindly by a physician. In addition, a monthly 
quality assurance program was used with periodic full dis- 
closure and analysis of recirculated known tapes, with 
adequate blinding into the analyst pool of tapes. Duplicate 
results were compared to determine accuracy and repeat- 
ability. Precision was >90% at any given time. 
Exercise treadmill test. A modified Bruce exercise proto- 
col was used for all patients. All patients underwent a 
screening exercise test before the study, and performed the 
exercise test at the same time of day for each placebo period. 
The variables that were systematically obtained for the 
analysis were: exercise duration, onset of I mm ST depres- 
sion and onset of chest pain. 
The following criteria were used to terminate the exercise 
test: 1) moderately severe chest pain (on a scale of 1 to 4, 4 
was the most severe). The test was stopped if a patient 
developed 3+ chest pain; 2) marked ST-T changes r3 mm; 
and 3) profound shortness of breath or fatigue. 
Data and statistical analysis. The details of the statistical 
methods are presented in the Appendix. Summary statistics 
were generated for each variable (Tables 1 and 2). The 
number of subjects includes those for whom at least two 
placebo replications were available. We calculated the stan- 
dard deviation and the mean value over replications (each 
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Table 2. Summary of Key Statistics of Ischemic Variables 
No. of 
Subiects 
Average Within Average Among 
Average Over Subjects Subjects Subjects 
cv % % 
Mean +SD (%) SD* Variation SD* Variation 
Exercise treadmill test 
Onset of chest pain (s) 49 334 60 19 81 30 124 70 
Onset of 1 mm ST depression (s) 43 270 66 28 108 33 154 61 
Total duration (s) 49 434 58 15 71 15 162 89 
Holter monitoring 
No. of episodes/24 h 44 2.7 1.2 44 1.2 27 2.0 73 
Total duration (mid24 h) 40 62 29 67 66 25 115 75 
Subjective symptoms 
Angina1 frequency 43 4.3 2.1 56 2.8 43 3.2 57 
Nitroglycerin consumption 42 3.8 1.7 55 2.0 27 3.3 13 
*Based on transforming log scale variance components, at mean variable values. CV = coefficient of variation; SD = standard deviation. 
placebo period is one replication) for each subject and then 
averaged both the standard deviation and the mean value 
over subjects. The coefficient of variation of each placebo 
period was also calculated for each subject and averaged 
over subjects (Table 2). The standard deviation among 
subjects within each placebo administration was calculated 
and averaged over the placebo administrations. 
In all other calculations, log transformations were applied 
[x to log(x t l)], because the standard deviation tended to 
increase linearly with the mean value. The relative amount 
of variation attributable to subject to subject differences and 
to administration to administration differences was calcu- 
lated with the statistical methods (18) outlined in the Appen- 
dix; the results are presented in Table 2. In addition, Tables 
3 and 4 show the results of the calculations, according to the 
formulas in the Appendix, for the minimal changes indicative 
of a treatment effect in an individual and the sample size for 
the designs of the clinical trials, respectively. 
Table 3. Minimal Individual Change (95% confidence range for 
changes in each variable) 
% Absolute 
Change* Change 
Exercise treadmill test 
Onset of chest pain (s) 4% 163 s 
Onset of 1 mm ST depression (s) 67% 181 s 
Total duration (s) 3% 169 s 
Holter monitoring 
No. of ischemic episodes/24 h 72% 1.9124 h 
Total duration (mm/24 h) 95% 59 mm/24 h 
Subjective symptoms 
Angina1 frequency 84% 3.6lwk 
Nitroglycerin consumption 77% 2.9lwk 
*Based on the change needed to be deemed significant at p = 0.05 for an 
individual. All variables transformed by log (x t 1). Absolute change is 
computed as the product of the percent change and the mean for this study. 
Results 
Of the 65 patients evaluated for this study, 11 were 
excluded because they needed antianginal treatment. The 
remaining 54 patients went through at least the first two 
placebo periods. Clinical and social factors prevented some 
patients from continuing in the study. In addition, because of 
differences in the clinical status among patients and various 
other circumstances, not all tests and variables could be 
obtained at each period. For example, some patients did not 
have chest pain during the exercise treadmill test; others did 
not have adequate ambulatory ECG (Holter) recordings for 
analysis. Other patients did not have precise measurements of 
duration of transient ischemic episodes for various reasons 
(that is, the tape ended before completion of ischemic epi- 
sodes; artifact occurred during ischemic episodes precluding 
the identification of the beginning or the end, or both, of 
ischemic episodes). As a result, the number of subjects for 
each variable on Table 1 does not match the “ideal” number 
(54 subjects). 
Variability of ischemic indexes (Tables 1 and 2). There 
were no significant differences in the mean value of each 
variable among all three placebo periods (Table 1). There was 
a slight reduction in the frequency of spontaneously occurring 
ischemic variables (angina1 frequency, nitroglycerin con- 
sumption, number of ischemic episodes and total ischemia on 
Holter monitoring) in the second and third placebo periods. 
Comparison of the mean data of each variable averaged 
over subjects (Table 2) indicated that the exercise ischemic 
variables had smaller coefficients of variation than did the 
Holter or subjective indexes. The highest exercise ischemic 
coefficient of variation was 28% for the onset of 1 mm ST 
depression, whereas the smallest coefficient of variation for 
the Holter indexes was 44%. Angina1 frequency and nitro- 
glycerin consumption had a relatively larger coefficient of 
variation (56 and 55%, respectively). 
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Table 4. Sample Size Required for 30% and 50% Expected Change at Different Numbers of Replications: Two Independent Samples 
Protocol Versus Matched Pairs Protocol 
Sample Size Required for 30% Expected Change Sample Size Required for 50% Expected Change 
Two Independent Matched Pairs Two Independent Matched Pairs 
Samples Protocol Protocol Samples Protocol Protocol 
Replications I 2 3 1 2 3 I 2 3 1 2 3 
Exercise treadmill test 
Onset chest pain (SI 
Onset of I mm ST depression (s) 
Total duration (s) 
Holter monitoring 
No. of episodes/24 hr 
Total duration (minl24 h) 
Subjective symptoms 
Angina frequencyiwk 
Nitroglycerin consumptioniwk 
26 22 21 5 3 2 8 6 6 2 2 2 
61 51 47 11 6 4 18 I5 1 4 2 2 
24 21 20 3 2 2 6 6 6 I I 1 
98 82 80 14 7 5 30 2s 20 5 3 2 
550 500 470 70 35 24 150 140 140 24 I2 10 
125 100 90 28 14 IO 32 2s 25 8 4 4 
130 112 108 I9 10 7 38 30 30 6 4 4 
The exercise rreadmill duration had the smallest percent 
variation within subjects; angina frequency had the largest. 
However, the percent variation among subjects was almost 
twice as large for indexes as that within subjects. 
Minimal individual changes for each index required to 
indicate the significant treatment effects (Table 3). The exer- 
cise ischemic variables required less percent change for the 
significant change attributable to treatment (39% for exercise 
duration, 49% for onset of chest pain and 67% for the onset 
of 1 mm ST depression) compared with that for Holter ECG 
variables (72% for number of episodes/24 h and 95% for total 
duration of myocardial ischemia), angina1 frequency (84%) 
and nitroglycerin consumption (77%). 
Sample size for a given percent change of each index. 
Table 4 compares the sample sizes required for 30% and 50% 
expected changes at a different number of replications and 
different designs. A two independent samples protocol 
needed a larger sample size than did a matched pair protocol. 
However, the need could be minimized by increasing the 
number of test replications. In the case of the matched pair 
protocol, an increase in the number of replications resulted 
in a very slight improvement in the sample size, and may not 
warrant multiple measurements. 
When various indexes were compared, exercise duration 
demanded the smallest sample size to reach a goal set for the 
given expected percent change (p value =0.05; 80% statisti- 
cal power). Whereas a modest sample size was required to 
reach a similar goal for the number of ischemic episodes on 
Holter monitoring, total duration of ischemia on Holter 
monitoring required a much larger sample size for the same 
expected change, as did angina1 frequency and nitroglycerin 
consumption. 
Discussion 
Our study, the first to compare the variability of different 
ischemic indexes in the same patients, showed that these 
indexes vary considerably both in spontaneously occurring 
myocardial ischemic episodes and exercise-induced epi- 
sodes. The variability is much larger among subjects than 
within subjects. This is expected because the wide range in 
the extent of coronary artery disease among subjects pro- 
vides different degrees of severity and different frequencies 
of myocardial ischemia, whereas fewer variables are in- 
volved in the development of myocardial ischemia in an 
individual. 
Reproducibility of various ischemic indexes: exercise- 
induced ischemia versus spontaneously occurring ischemia. 
The variability of ischemic indexes occurred more markedly 
in spontaneously occurring ischemic episodes detected by 
Holter monitoring and in subjective symptoms compared 
with exercise-induced ischemic episodes (Table 2). Our 
findings on the reproducibility of exercise variables are 
similar to those of others (19-25). However, the 15% coef- 
ficient of variation for total exercise time from our data is 
slightly higher than the 5% reported by Smokler et al. (19), 
5% described by Lassvik (20) and 6% reported by Sullivan et 
al. (21). This difference is probably due to the different end 
points for terminating the exercise treadmill test. Also, our 
study encompassed three placebo periods at weekly inter- 
vals; in contrast, the other studies described day to day 
variability of ischemic episodes. Yet, our study is in line with 
those of other investigators (22-24) who found that exercise 
duration is indeed reproducible, even after weeks of placebo 
treatment, although there is a slight increase in the exercise 
performance during subsequent tests. 
Interestingly, our data indicate that the exercise ischemic 
variables are more sensitive than Holter ECG monitoring for 
detecting changes within a subject caused either by thera- 
peutic treatment or by progression of the disease. This is 
probably a result of several factors: 1) exercise-induced 
ischemia is more reproducible than is spontaneously occur- 
ring &hernia; and 2) some of the ST-T changes detected on 
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Holter monitoring may not truly represent myocardial isch- 
emia and are not, therefore, reproducible. Our observation 
that the spontaneous variation of myocardial ischemic epi- 
sodes detected on Holter monitoring is similar to that of 
others (26,27). 
Assessment of individual antianginal treatment. To judge 
whether or not antianginal treatment for an individual patient 
is effective, one must account for the natural variability of 
each index. Exercise ischemic variables require a smaller 
change (41% to 67%) than do the Holter and subjective 
indexes (72% to 95%). However, the onset of 1 mm ST 
depression requires approximately the same degree of min- 
imal detectable changes as does the number of episodes 
detected by Holter monitoring. In general, an improvement 
of approximately 2.5 min on exercise variables is required to 
ascertain the benefit from a particular intervention for anti- 
ischemic therapy. Sullivan et al. (21) also found that a 
change of approximately 2 min in exercise time and onset of 
angina during exercise treadmill testing is required to indi- 
cate significant treatment effects. For spontaneous ischemic 
variables, our data show that the reduction of at least two 
ischemia episodes/24 h or 59 min in duration of myocardial 
ischemia on Holter monitoring or four episodes of angina1 
attacks per week are required to establish significant anti- 
ischemic effects. 
Sample size for the antianginal study design. By allowing 
a comparison of the variability of each index, our study 
provides an insight into the design of an antianginal study, 
especially with respect to the sample size and the number of 
measurements required to establish a given expected im- 
provement of each index. The matched pairs protocol de- 
sign, which compares baseline and treatment values in the 
same patients, requires a much smaller sample size than 
does the two independent samples protocol. In addition, the 
larger the expected percent change, the smaller the sample 
size needed. An increase in the number of replications 
significantly reduces the sample size (Table 4). However, 
increasing the number of replications beyond three in the 
matched pairs protocol does not significantly reduce the 
sample size further. In fact, our data indicate that two 
replications are sufficient for all variables in the matched 
pairs protocol. 
Conclusions. We have demonstrated that all ischemic 
variables, both from spontaneously occurring myocardial 
ischemia and from exercise-induced ischemia, vary substan- 
tially. As expected, the exercise variables are the most 
reproducible. Our data can be used to determine the signif- 
icant antianginal effects for individuals and for the design of 
clinical trials. However, the present study cannot be used to 
infer which variables are most useful for guiding antianginal 
treatment. Nor does it imply that using the minimal detect- 
able change criteria in either of the variables will prevent 
major cardiac ischemic events. Nevertheless, our study 
emphasizes that the variability of all indexes, including 
exercise testing and Holter monitoring, must be taken into 
account before any conclusions regarding the efficacy of 
angina1 treatment or intervention are drawn. 
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Appendix 
Calculation of Component of Variance 
E 2 (yi. - y..)* - (a - l)V, 
where V, = within subject variance component; V, = among 
subject variance component; Y, = log value for the jth placebo 
administration for the ith subject; a = number of subjects; N = total 
number of observations; yi. = mean of ni observations for the ith 
subject; and 7.. = mean over all N observations. 
The last two columns of Table 2 present these variance compo- 
nents as the percent of variation attributable to administration to 
administration differences and to subject to subject differences, 
using V, t V, as total variation. In addition, within subject and 
among subject standard deviations were obtained from V, and V,, 
respectively. These standard deviations are estimated for a subject 
with variables at the mean values observed in the study. 
Calculation of Sample Sizes for Future Studies 
The number of subjects and the number of administrations per 
subject that are needed in a study to have a high (80%) power of 
detecting differences of magnitude (D), using p = 0.05, can be 
determined from our results. The formulas for k administrations are 
as follows: 
1) Two independent samples protocol: 
Number of subjects per group = 1 t 15.7 
D* * 
2) Matched pairs protocol: 
Number of subjects = 2 t 7.85 - 
D2 ’ 
Minimal samples sizes for the study designs and the variables 
used can be determined to present the trade-off between repeated 
measurements and number of subjects, and to yield sample size 
estimates for planning studies. A significance level of 0.05 and a 
statistical power of 80% were used in these formulas. 
JACC Vol. 13, No. 3 NADEMANEE ET AL. 579 
March 1, 1989:574-9 VARIABILITY OF MYOCARDIAL ISCHEMIC INDEXES 
Calculation of “Significant” Treatment Effect in an Individual 
The minimal percent change in a variable between placebo and 
treatment that would be needed to indicate a significant (p < 0.05) 
effect was calculated as follows: 
Percent change = 100 (1 - exp [-1.96mw]) 
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